Richard Pzena's BMY Position Overview
Richard Pzena (via Pzena Investment Management LLC) currently holds 14.9M shares of Bristol-Myers Squibb Company (BMY) worth $672.06 M, representing 2.17% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Richard Pzena has maintained a strategic position in BMY, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 6.7M shares. Largest reduction occurred in Q4 2024, reducing 900.4K shares.
Analysis based on 13F filings available since 2013 Q2
Richard Pzena's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Richard Pzena
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2019 | +2.58 M | New Buy | 2.58 M | $50.71 |
| Q4 2019 | -39,851 | Reduce 1.55% | 2.54 M | $64.19 |
| Q1 2020 | -701,418 | Reduce 27.64% | 1.84 M | $55.74 |
| Q2 2020 | -373,749 | Reduce 20.35% | 1.46 M | $58.80 |
| Q3 2020 | -6,644 | Reduce 0.45% | 1.46 M | $60.29 |
| Q4 2020 | +366 | Add 0.03% | 1.46 M | $62.03 |
| Q1 2021 | +4,862 | Add 0.33% | 1.46 M | $63.13 |
| Q2 2021 | -1,369 | Reduce 0.09% | 1.46 M | $66.82 |
| Q3 2021 | -281,980 | Reduce 19.31% | 1.18 M | $59.17 |
| Q4 2021 | -22,235 | Reduce 1.89% | 1.16 M | $62.35 |
| Q1 2022 | +2.47 M | Add 213.73% | 3.63 M | $73.03 |
| Q2 2022 | +545,445 | Add 15.04% | 4.17 M | $77.00 |
| Q3 2022 | -179,101 | Reduce 4.29% | 3.99 M | $71.09 |
| Q4 2022 | -131,559 | Reduce 3.30% | 3.86 M | $71.95 |
| Q1 2023 | +651,213 | Add 16.87% | 4.51 M | $69.31 |
| Q2 2023 | -184,216 | Reduce 4.08% | 4.33 M | $63.95 |
| Q3 2023 | +596,625 | Add 13.79% | 4.92 M | $58.04 |
| Q4 2023 | +668,622 | Add 13.58% | 5.59 M | $51.31 |
| Q1 2024 | +6.7 M | Add 119.82% | 12.29 M | $54.23 |
| Q2 2024 | +1.84 M | Add 14.97% | 14.13 M | $41.53 |
| Q3 2024 | +67,409 | Add 0.48% | 14.2 M | $51.74 |
| Q4 2024 | -900,447 | Reduce 6.34% | 13.3 M | $56.56 |
| Q1 2025 | +157,527 | Add 1.18% | 13.46 M | $60.99 |
| Q2 2025 | +1.38 M | Add 10.29% | 14.84 M | $46.29 |
| Q3 2025 | +58,129 | Add 0.39% | 14.9 M | $45.10 |
Richard Pzena's Bristol-Myers Squibb Company Investment FAQs
Richard Pzena first purchased Bristol-Myers Squibb Company (BMY) in Q3 2019, acquiring 2,577,726 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Richard Pzena has held Bristol-Myers Squibb Company (BMY) for 25 quarters since Q3 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Richard Pzena's largest addition to Bristol-Myers Squibb Company (BMY) was in Q1 2024, adding 12,293,913 shares worth $666.7 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Richard Pzena's firm, Pzena Investment Management LLC, owns 14,901,604 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $672.06 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 2.17% of Richard Pzena's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Richard Pzena's peak holding in Bristol-Myers Squibb Company (BMY) was 14,901,604 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.